BTCY Company Profile and Key Details

BTCY has shown weak momentum, losing -38.25% over the past week and -64.38% over the past quarter, though year-to-date performance is down -59.73%. Short-term trend indicators are bullishly aligned (SMA20 -40.42%, SMA50 -48.56%, SMA200 -57.5%). The stock’s 14-day RSI is 21.43 (weak momentum), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -83.22% below its high and over 5.15% above its low. Average 10-day trading volume of 46.37 thousand shares is below the 3-month average of 72.86 thousand, indicating normal recent market interest.

Biotricity, Inc. generated EPS of -$1.65 over the past year. Five-year average earnings growth is -1.46%. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at $nan. Next year's EPS is expected at $68.21. Biotricity, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended February 11, 2026, missed forecasts by -50.0%. The prior quarter beat by -62.5%. Over the last six quarters, Apple has recorded several small beats. These include 30.56% in June 26, 2024.

Biotricity, Inc. has 28.44 million shares outstanding. The public float is 16.56 million shares, elevated short interest at 2.25% of float. This equals 459.95 thousand shares. The short ratio is 5.5 days. Institutional investors hold 3.06% of the float. Insiders own 39.37%.

Biotricity, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.15. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.10 and $0.75. With a market capitalization of about $3.55 million, Biotricity, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.15). Key stats such as the average daily volume over the past year has been around 68.53 thousand shares, volume is running light vs its 52-week average. Headquartered in Redwood City, CA, Biotricity, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Waqaas Al-Siddiq, the company employs approximately 55 people and listed since February 16, 2018. Headquartered in Redwood City, California, Biotricity, Inc. is a medical technology enterprise delivering biometric data monitoring solutions, primarily within the United States.

Biotricity, Inc. trades at a P/E ratio of -0.68, slightly below the S&P 500 average, with a price-to-sales ratio of 0.23 and a price-to-book ratio of -0.11 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.23, also above market averages.

Biotricity, Inc. (NASDAQ:BTCY) shares are down -59.73% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Biotricity, Inc. trading at a premium to the broader market with a P/E of -0.68. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.33, suggesting 3364.0% upside. Our AI forecast model points to short-term weakness (-28.0% over two weeks), a medium-term rise (12.0% over three months), and a longer-term loss (-36.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Biotricity, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -28.0%, with price expected at $0.09 by July 10, 2026, within a range of $0.05 to $0.13 3-Month Outlook: Projected rise of 12.0%, reaching $0.14 by September 24, 2026, with a range of $0.12 to $0.16. 1-Year Outlook: Projected loss of -36.0%, with price at $0.08 by June 25, 2027, within a range of $0.00 to $0.00.